https://rheumatologydigest.org/tags/iptacopan/Recent content in Iptacopan on Rheumatology DigestHugoen-usMon, 03 Aug 2026 05:00:00 +0530https://rheumatologydigest.org/posts/applause-iptacopan-igan/Mon, 03 Aug 2026 05:00:00 +0530https://rheumatologydigest.org/posts/applause-iptacopan-igan/Final 24-month data from APPLAUSE-IgAN: the oral factor B inhibitor iptacopan roughly halved the rate of eGFR decline in high-risk IgA nephropathy (−3.10 vs −6.12 ml/min/1.73 m²/year) and cut hard kidney-failure events from 33.5% to 21.4%, converting an accelerated approval based on proteinuria into evidence on preserved kidney function — with serious infection the trade-off to manage.